Solid Neoplasm
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
An Annexin V/PI double staining assay further showed that B7-H1 expressed by SP6.5 cells did not increase the apoptosis of T-cells, though it was found in a variety of other solid tumors.
|
21461580 |
2011 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Immunotherapies targeting the PD-1/PD-L1 pathway have shown durable antitumor effects in a subset of patients with solid tumors.
|
23674495 |
2013 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The anti-PD-1 strategy can be effective in several solid tumors such as renal cell carcinoma (RCC) or non-small cell lung cancer (NSCLC), however in this review we summarize the biological role of PD-1/PD-L1 on cancer by focusing our attention in the biological rationale, clinical challenges and opportunities to target the PD-1/PD-L1 axis in melanoma.
|
24029602 |
2014 |
Solid Neoplasm
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Our study demonstrated the utility of exploring the expression of two potentially targetable immune checkpoint proteins (PD-1/PD-L1) in a substantial proportion of solid tumors, including some aggressive subtypes that lack other targeted treatment modalities.
|
25392179 |
2014 |
Solid Neoplasm
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
The potential predictive role of programmed death-ligand-1 (PD-L1) expression on tumor cells in the context of solid tumor treated with checkpoint inhibitors targeting the PD-1 pathway represents an issue for clinical research.
|
26086854 |
2015 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
To clarify a precise determinant of the clinical significance of PD-L1, we conducted a meta-analysis to evaluate the overall risk of PD-L1 on survival for patients with solid tumors.
|
26323922 |
2015 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Pembrolizumab (MK-3475, lambrolizumab, Keytruda(®)) is a PD-1 inhibitor that has shown clinical activity in a variety of solid tumors and is currently approved for the second-line treatment of PD-L1-positive non-small-cell lung cancer and for unresectable/metastatic melanoma.
|
26631501 |
2016 |
Solid Neoplasm
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Secondary objectives included objective response rate and 24-week progression-free survival rate (per Response Evaluation Criteria in Solid Tumors version 1.1); exploratory objectives included overall survival (OS) and response by tumor programmed death ligand-1 expression.
|
27354481 |
2016 |
Solid Neoplasm
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Solid tumors with CD8 T-cell rich tumor microenvironment have been implicated to be associated with increased PD-L1 expression.
|
27465786 |
2016 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Immunotherapy, targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and the programmed cell death 1 (PD-1) receptor and its ligand (PD-L1) have shown tremendous improvements in the survival of patients with advanced solid tumors.
|
27859479 |
2017 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Targeted immunotherapy based on PD-1/PD-L1 suppression has revolutionized the treatment of various solid tumors.
|
27861596 |
2016 |
Solid Neoplasm
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
The primary endpoint was independently confirmed objective response rate per Response Evaluation Criteria in Solid Tumors version 1.1 (central review), assessed in prespecified subgroups based on PD-L1 expression and in all patients.
|
27939400 |
2017 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Immune checkpoint inhibition, in particular along the programmed cell death protein 1 (PD-1)/B7-H1 (PD-L1) axis, is an established strategy in solid tumors with potential as an adjunctive therapy in hematologic malignancies.
|
28062906 |
2017 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Immunotherapy has moved to the center stage of cancer treatment with the recent success of trials in solid tumors with PD-1/PD-L1 axis blockade.
|
28213726 |
2017 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Overall, our data document the superiority of local production of PD-L1 mini-body by CAd-VEC<i>PDL1</i> combined with administration of tumor-directed CAR T cells to control the growth of solid tumors.<i></i>.
|
28235763 |
2017 |
Solid Neoplasm
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
PD-L1/2 expression in solid tumors inhibits chimeric antigen receptor (CAR) T-cell efficacy.
|
28344886 |
2017 |
Solid Neoplasm
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
These preclinical data support the ongoing clinical investigation of the cergutuzumab amunaleukin immunocytokine with abolished CD25 binding for the treatment of CEA-positive solid tumors in combination with PD-L1 checkpoint blockade and ADCC competent antibodies.
|
28405498 |
2017 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The combined therapeutic potential of an immunocytokine designed to deliver IL-12 to the necrotic regions of solid tumors with an anti-PD-L1 antibody that disrupts the immunosuppressive PD-1/PD-L1 axis yielded a combinatorial benefit in multiple murine tumor models.
|
28423552 |
2017 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Identification of a novel PD-L1 positive solid tumor transplantable in HLA-A*0201/DRB1*0101 transgenic mice.
|
28430664 |
2017 |
Solid Neoplasm
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
The findings of this meta-analysis suggest the correlation of PD-L1 overexpression with worse OS in patients with solid tumors.
|
28471952 |
2017 |
Solid Neoplasm
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Expression of PD-1, PD-L1, and PD-L2 is low in pediatric solid tumors.
|
28488345 |
2017 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Purpose The multicohort phase Ib KEYNOTE-028 (NCT02054806) study was designed to evaluate the safety and efficacy of pembrolizumab, an anti-programmed death 1 monoclonal antibody, in patients with programmed death ligand 1 (PD-L1) -positive advanced solid tumors.
|
28489510 |
2017 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Monoclonal antibodies (mAbs) directed against PD-1/PD-L1 have recently entered the therapeutic algorithm of several solid tumors.
|
28595514 |
2017 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Patients and Methods KEYNOTE-028 (NCT02054806) is a nonrandomized, multicohort, phase Ib trial of pembrolizumab in patients with PD-L1-positive advanced solid tumors.
|
28837405 |
2017 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
LV305 is currently being evaluated in phase 1 and 2 trials in metastatic recurrent cancer patients with NY-ESO-1 positive solid tumors as a single agent and in combination with anti-PD-L1.
|
28891906 |
2017 |